Bionical Emas launches Managed Access Program for JZP 458 - a recombinant Crisantaspase produced in Pseudomonas fluorescens
(0) WILLINGTON, England, April 8, 2021 /PRNewswire/ -- Bionical Emas, a global specialist Clinical Research Organization (CRO) has today announced the launch of a Managed Access Program for Jazz Pharmaceuticals' medicinal product JZP-458 for the treatment of patients with Acute Lymphoblastic Leukaemia (ALL) and Lymphoblastic Lymphoma (LBL) following hypersensitivity to E. Coli-derived asparaginases. The Managed Access Program provides a mechanism through which unsolicited physician requests, to fulfil the special need of a patient can be supported. " JZP-458 provides a further therapy option ...
Source: finanznachrichten.de
